Avadel Pharmaceuticals PLC (AVDL) Stock Price & Overview
NASDAQ:AVDL • IE00BDGMC594
Current stock price
The current stock price of AVDL is 21.64 USD. Today AVDL is up by 0.05%. In the past month the price increased by 0.74%. In the past year, price increased by 151.34%.
AVDL Key Statistics
- Market Cap
- 1.96B
- P/E
- N/A
- Fwd P/E
- 26.23
- EPS (TTM)
- N/A
- Dividend Yield
- N/A
AVDL Stock Performance
AVDL Stock Chart
AVDL Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to AVDL. When comparing the yearly performance of all stocks, AVDL is one of the better performing stocks in the market, outperforming 94.6% of all stocks.
AVDL Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to AVDL. While AVDL has a great health rating, there are worries on its profitability.
AVDL Earnings
AVDL Forecast & Estimates
16 analysts have analysed AVDL and the average price target is 21.48 USD. This implies a price decrease of -0.75% is expected in the next year compared to the current price of 21.64.
For the next year, analysts expect an EPS growth of 138.39% and a revenue growth 62.59% for AVDL
AVDL Groups
Sector & Classification
AVDL Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -0.14% | ||
| ROE | -0.28% | ||
| Debt/Equity | 0.35 |
AVDL Ownership
AVDL Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.76 | 900.456B | ||
| JNJ | JOHNSON & JOHNSON | 20.87 | 587.99B | ||
| MRK | MERCK & CO. INC. | 23.36 | 298.764B | ||
| PFE | PFIZER INC | 9.48 | 162.403B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.41 | 125.711B | ||
| ZTS | ZOETIS INC | 16.66 | 49.512B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.4 | 27.972B | ||
| VTRS | VIATRIS INC | 5.36 | 15.693B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.94 | 11.495B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.787B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.274B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.606B | ||
| CORT | CORCEPT THERAPEUTICS INC | 51.43 | 4.465B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About AVDL
Company Profile
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. The company is headquartered in Dublin, Dublin. The firm's product, LUMRYZ, is an extended-release formulation of sodium oxybate, indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the challenges patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME, and MEDUSA. Its MICROPUMP technology allows for the development of modified-release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified-release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.
Company Info
IPO: 1952-01-16
Avadel Pharmaceuticals PLC
10 EARLSFORT TERRACE, Ballycoolin
DUBLIN DUBLIN D02 IE
CEO: Gregory J. Divis
Employees: 188
Phone: 356364491830
Avadel Pharmaceuticals PLC / AVDL FAQ
Can you describe the business of Avadel Pharmaceuticals PLC?
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. The company is headquartered in Dublin, Dublin. The firm's product, LUMRYZ, is an extended-release formulation of sodium oxybate, indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the challenges patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME, and MEDUSA. Its MICROPUMP technology allows for the development of modified-release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified-release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.
What is the current price of AVDL stock?
The current stock price of AVDL is 21.64 USD. The price increased by 0.05% in the last trading session.
What is the dividend status of Avadel Pharmaceuticals PLC?
AVDL does not pay a dividend.
What is the ChartMill technical and fundamental rating of AVDL stock?
AVDL has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
How is the market expecting AVDL stock to perform?
16 analysts have analysed AVDL and the average price target is 21.48 USD. This implies a price decrease of -0.75% is expected in the next year compared to the current price of 21.64.
Would investing in Avadel Pharmaceuticals PLC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on AVDL.
Is Avadel Pharmaceuticals PLC (AVDL) expected to grow?
The Revenue of Avadel Pharmaceuticals PLC (AVDL) is expected to grow by 62.59% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.